Search

AG0301-COVID19

The candidate is a plasmid DNA vaccine developed using an intradermal gene transfer method targeting the SARS-CoV-2 spike protein. … AG0301-COVID19 is a vaccine candidate developed by AnGes Inc. and Osaka University.

NLX-P101

NLX-P101 is being evaluated as a therapeutic drug when injected into this deep brain structure that is known to function abnormally in Parkinson’s patients.

PYM50018

PYM50018 is a patented, orally active, neuroprotective and neuroregenerative compound. It is developed for the treatment of amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease). … When administered orally to a transgenic pre-clinical model of ALS, PYM50018 delays the loss of muscle strength and extends survival time.

UB-612

The vaccine incorporates a strong S1-RBD component linked to a single chain fragment region (sFC) of a human IgG1, which facilitates cell attachment and acts as the principal neutralizing domain of the … This vaccine was designed to induce a broad immune response. It was able to reduce viral load and prevent COVID-19 infection in a mouse challenge model and in rhesus macaques[L30653, L30658].

NTx-265

NTx-265 is a combination of two currently marketed large molecules designed to stimulate the growth and differentiation of neural stem cells in adults who have suffered a stroke – the second leading cause … In May 2006, biotechnology company Stem Cell Therapeutics started a Phase IIa study of NTx-265.

Nizubaglustat

Nizubaglustat is a small molecule drug. The usage of the INN stem '-glustat' in the name indicates that Nizubaglustat is a ceramide glucosyltransferase inhibitor. … Nizubaglustat has a monoisotopic molecular weight of 433.23 Da.

AIT-034

There is some evidence that AIT-034 could complement Neotrofin as a treatment for Alzheimer's disease and dementia. … AIT-034 is a distinct chemical analog of hypoxanthine and pyrollidone that has been demonstrated in animal studies to enhance memory and to reverse memory deficits in severely impaired animals that do

SP1049C

SP1049C is a novel anthracycline chemotherapeutic agent containing [doxorubicin] and two nonionic pluronic block copolymers. … [A260416] It is designed to overcome drug resistance in a number of cancers. It has successfully completed Phase 1 trials. Phase 2 results are currently under final review.

Oglufanide

Oglufanide works as a regulator of the body's immune response, is being given by intranasal administration to patients with chronic hepatitis C viral infection. … Oglufanide is a synthetic dipeptide immunomodulator in development for the treatment of chronic hepatitis C viral infection.

RG-7795